Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry

Study Overview
=================
Brief Summary
-----------------
To assess potential link between unrecognized myocardial inflammation (myocarditis) and premature ventricular contractions (PVCs) associated with and without reduced Left ventricular ejection fraction (LVEF) through comprehensive diagnostic work up.

Detailed Description
-----------------
Hypothesized that occult inflammation is clinically under-recognized in patients with symptomatic PVCs with and without Left ventricular (LV) dysfunction and can be a potential link between the 2 conditions. Aimed to evaluate the incidence of underlying inflammation using the Positron emission tomography (PET) scan in patients presenting with symptomatic PVCs enrolled retrospectively in the MAVERIC registry.

Official Title
-----------------
Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry

Conditions
-----------------
Myocarditis, Premature Ventricular Contractions, Ventricular Tachycardia (VT)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients > 18 years of age with mono-morphic or polymorphic PVC burden of ≥5000 in 24 hours. Non-sustained VT was defined as ≥3 more consecutive beats lasting <30 seconds Exclusion Criteria: History of myocardial infarction, Significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or CT angiography, History of revascularization, Significant symptomatic atrial arrhythmias associated with LV dysfunction, Severe valvular disease, Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, History of cardiac arrest, History of channelopathies or inherited arrhythmias.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify the underlying myocarditis in patients presenting with PVCs with or without reduced LVEF | To identify the underlying myocarditis in patients presenting with PVCs with or without reduced LVEF through laboratory testing, FDG-PET(18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose - positron emission tomography) scan, Cardiac Magnetic Resonance imaging and/or Endomyocardial biopsy. | Retrospective Collection between dates January 2014-January 2023 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ascertain whether immunosuppressive therapy (IST) affords short term and long term improvement of LVEF and clinical outcomes | To ascertain whether immunosuppressive therapy (IST) affords short term and long term improvement of LVEF and clinical outcomes in virus negative and FDG-PET positive patients with non-ischemic cardiomyopathy, myocardial inflammation and PVCs. | Retrospective Collection between dates January 2014-January 2023 |